SLC5A2 and atrial fibrillation: Since the emergence of sodium–glucose co-transporter 2 (SGLT2) inhibitors as drugs capable of reducing hospitalization for heart failure (HF) or cardiovascular death in a wide range of clinical conditions, several studies have sought to demonstrate their benefit on other cardiovascular outcomes.1-7 One interesting line of research focuses on evaluating the potential role of SGLT2 inhibitors in the prevention of atrial fibrillation (AF).